{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:49:20Z","timestamp":1790470160453,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.leukres.2020.106337","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T11:36:40Z","timestamp":1582630600000},"page":"106337","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Novel therapeutic approaches in chronic myeloid leukemia"],"prefix":"10.1016","volume":"91","author":[{"given":"Nurg\u00fcl","family":"\u00d6zg\u00fcr Yurtta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2020.106337_bib0010","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10637-017-0457-9","article-title":"MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant BcrAbl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells","volume":"35","author":"Yeh","year":"2017","journal-title":"Invest. New Drugs"},{"issue":"4944","key":"10.1016\/j.leukres.2020.106337_bib0015","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.leukres.2020.106337_bib0020","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","article-title":"Chronic myeloid leukaemia as a model of disease evolution in human cancer","volume":"7","author":"Melo","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.leukres.2020.106337_bib0025","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/bcp.13637","article-title":"Evolving treatment strategies in CML - moving from early and deep molecular responses to TKI discontinuation and treatment-free remission: is there a need for longer-term trial outcomes?","volume":"84","author":"Eskazan","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.leukres.2020.106337_bib0030","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","article-title":"Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine kinase inhibitor era: analysis of patient data from six prospective clinical trials","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0035","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/2040620717719851","article-title":"Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update","volume":"8","author":"Eskazan","year":"2017","journal-title":"Ther. Adv. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2020.106337_bib0040","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENEST freedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.leukres.2020.106337_bib0045","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2020.106337_bib0055","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosomepositive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0060","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14728214.2018.1445717","article-title":"Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia","volume":"23","author":"Kavanagh","year":"2018","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"6","key":"10.1016\/j.leukres.2020.106337_bib0065","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2020.106337_bib0070","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2020.106337_bib0075","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-09-1068","article-title":"Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia","volume":"15","author":"Milojkovic","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0080","doi-asserted-by":"crossref","first-page":"e601","DOI":"10.1038\/bcj.2017.84","article-title":"CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients","volume":"7","author":"Matsushita","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.leukres.2020.106337_bib0085","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/blood-2016-09-696013","article-title":"The chronic myeloid leukemia stem cell: stemming the tide of persistence","volume":"129","author":"Holyoake","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0090","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/MOH.0000000000000403","article-title":"Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents","volume":"25","author":"Talati","year":"2018","journal-title":"Curr. Opin. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0095","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0100","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1096\/fj.13-236992","article-title":"BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein","volume":"28","author":"Buffa","year":"2014","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0105","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0110","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Philipp le Coutre","year":"2000","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.leukres.2020.106337_bib0115","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1158\/1078-0432.CCR-17-0962","article-title":"High BCR-ABL\/GUSIS levels at diagnosis of chronic phase cml are associated with unfavorable responses to standard-dose Imatinib","volume":"23","author":"Vigneri","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.leukres.2020.106337_bib0120","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate","volume":"108","author":"Jordanides","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2020.106337_bib0125","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.leukres.2020.106337_bib0130","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djn188","article-title":"Association between imatinibresistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase","volume":"100","author":"Wu","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.leukres.2020.106337_bib0135","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/leu.2016.51","article-title":"A role for FOXO1 in BCR-ABL1 independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"30","author":"Wagle","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation-2017.1.115","article-title":"Novel approaches to therapy in CML","volume":"2017","author":"Bhatia","year":"2017","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"10","key":"10.1016\/j.leukres.2020.106337_bib0145","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1182\/blood.V99.10.3792","article-title":"Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation","volume":"99","author":"Holtz","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0150","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2020.106337_bib0155","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1182\/blood-2003-04-1271","article-title":"BCR\/ABL kinase inhibition by imatinibmesylateenhancesMAPkinaseactivityinchronicmyelogenous leukemia CD341 cells","volume":"103","author":"Chu","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0160","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"7647","key":"10.1016\/j.leukres.2020.106337_bib0165","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.leukres.2020.106337_bib0170","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/leu.2017.264","article-title":"Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib","volume":"31","author":"Qiang","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2020.106337_bib0175","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/blood.V126.23.138.138","article-title":"ABL001, a potent allosteric inhibitor of BCR-ABL, exhibits safety and promising single-agent activity in a phase 1 study of patients with CML with the failure of prior TKI therapy","volume":"126","author":"Ottoman","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.leukres.2020.106337_bib0180","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"October (4)","key":"10.1016\/j.leukres.2020.106337_bib0185","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric ABL1 Inhibitor Asciminib (ABL001) with Ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-012-0150-1","article-title":"Signal transduction in the chronic leukemias: implications for targeted therapies","volume":"8","author":"Ahmed","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"11","key":"10.1016\/j.leukres.2020.106337_bib0195","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO.1999.17.11.3631","article-title":"Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development","volume":"17","author":"Rowinsky","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0200","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1039\/C7MD00030H","article-title":"New tricks for human farnesyltransferase inhibitor: cancer and beyond","volume":"8","author":"Wang","year":"2017","journal-title":"Medchemcomm"},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0205","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2020.106337_bib0210","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/asheducation-2008.1.427","article-title":"Novel agents in CML therapy: tyrosine kinase inhibitors and beyond","author":"Melo","year":"2008","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0215","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2002-07-1973","article-title":"Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0220","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/cncr.23006","article-title":"Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0225","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cncr.21590","article-title":"Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy","volume":"106","author":"Borthakur","year":"2006","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.leukres.2020.106337_bib0230","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0235","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2141.2009.07657.x","article-title":"Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies","volume":"145","author":"Teachey","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0240","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.leukres.2020.106337_bib0245","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jcb.25559","article-title":"Targeting the mTOR pathway in leukemia","volume":"117","author":"Dinner","year":"2016","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0250","first-page":"461","article-title":"Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia","volume":"27","author":"Li","year":"2012","journal-title":"Oncol. Rep."},{"issue":"10","key":"10.1016\/j.leukres.2020.106337_bib0255","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/sj.leu.2403848","article-title":"Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib","volume":"19","author":"Dengler","year":"2005","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0260","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1073\/pnas.0400063101","article-title":"Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs","volume":"101","author":"Mohi","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0265","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.leukres.2009.07.012","article-title":"mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein","volume":"34","author":"Mancini","year":"2010","journal-title":"Leuk. Res."},{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0270","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jcb.22380","article-title":"RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia","volume":"109","author":"Mancini","year":"2010","journal-title":"J. Cell. Biochem."},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0275","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD341 cells in vitro and in vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.leukres.2020.106337_bib0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.leukres.2018.10.002","article-title":"A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease","volume":"74","author":"Sweet","year":"2018","journal-title":"Leuk. Res."},{"issue":"6","key":"10.1016\/j.leukres.2020.106337_bib0285","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2016.36","article-title":"Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia","volume":"114","author":"Ceccacci","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0290","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.leukres.2020.106337_bib0295","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.yexcr.2018.07.017","article-title":"HDAC inhibitor suppresses proliferation and tumorigenicity of drugresistant chronic myeloid leukemia stem cells through regulation of hsamiR-196a targeting BCR\/ABL1","volume":"370","author":"Bamodua","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"29","key":"10.1016\/j.leukres.2020.106337_bib0300","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.leukres.2020.106337_bib0305","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3816\/CLK.2007.n.025","article-title":"Emerging role of aurora kinase inhibitors in chronic myeloid leukemia","volume":"1","author":"Alvarado","year":"2007","journal-title":"Clin Leuk."},{"key":"10.1016\/j.leukres.2020.106337_bib0310","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2015.00278","article-title":"Aurora kinase inhibitors: current status and outlook","volume":"5","author":"Bavetsias","year":"2015","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.leukres.2020.106337_bib0315","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of aurora kinases","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0320","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/leu.2012.186","article-title":"MK-0457, an aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.leukres.2020.106337_bib0325","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.leukres.2012.03.025","article-title":"Gadd45a transcriptional induction elicited by the aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor","volume":"36","author":"Mancini","year":"2012","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0330","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1517\/13543784.2012.652303","article-title":"Danusertib, an aurora kinase inhibitor","volume":"21","author":"Hielke","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.leukres.2020.106337_bib0335","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"91","author":"Artur Gontarewicz","year":"2008","journal-title":"Blood."},{"issue":"7569","key":"10.1016\/j.leukres.2020.106337_bib0340","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature15248","article-title":"Erosion of the chronic myeloid leukaemia stem cell pool by PPARg agonists","volume":"525","author":"Prost","year":"2015","journal-title":"Nature."},{"issue":"10","key":"10.1016\/j.leukres.2020.106337_bib0345","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/cncr.30490","article-title":"French CML Group. Pioglitazone together with imatinib in chronic myeloid leukemia: a proof of concept study","volume":"123","author":"Rousselot","year":"2017","journal-title":"Cancer."},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0350","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0355","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer."},{"issue":"17","key":"10.1016\/j.leukres.2020.106337_bib0360","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2005.11.981","article-title":"Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate","volume":"23","author":"J-PJ","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0365","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.clml.2013.03.020","article-title":"Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib","volume":"13","author":"Cortes","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0370","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40487-018-0058-6","article-title":"A review of omacetaxine: a chronic myeloid leukemia treatment resurrected","volume":"6","author":"Winer","year":"2018","journal-title":"Oncol. Ther."},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0375","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40259-017-0225-6","article-title":"Guilhot F. Chronic myeloid leukemia: immunobiology and novel immunotherapeutic approaches","volume":"31","author":"Cayssials","year":"2017","journal-title":"BioDrugs"},{"issue":"4","key":"10.1016\/j.leukres.2020.106337_bib0380","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ijc.2910430410","article-title":"Natural killer cell immunode\ufb01ciency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells","volume":"43","author":"Chang","year":"1989","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0385","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/leu.2011.239","article-title":"NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice","volume":"26","author":"Chen","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0390","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1182\/blood-2002-06-1841","article-title":"Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration","volume":"101","author":"Dong","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2020.106337_bib0395","series-title":"Teva Pharmaceuticals USA, Inc. SynriboTM. North Wales, PA: Teva Pharmaceuticals USA, Inc.","year":"2015"},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0400","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and ef\ufb01cacy of the combination of pegylated interferon-a2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"issue":"26","key":"10.1016\/j.leukres.2020.106337_bib0405","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2020.106337_bib0410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155959","article-title":"Interferon-\u03b1 revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients","volume":"11","author":"Polivkova","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0415","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)00027-1","article-title":"Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study","volume":"2","author":"Nicolini","year":"2015","journal-title":"Lancet Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0420","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Hjorth-Hansen","year":"2016","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2020.106337_bib0425","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2019-123674","article-title":"The combination of nilotinib + pegylated IFN alpha 2a provides somewhat higher cumulative incidence rates of MR4.5 at M36 versus nilotinib alone in newly diagnosed CP CML patients. Updated results of the petals phase III national study","volume":"134","author":"Nicolini","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2020.106337_bib0430","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2019-130043","volume":"134","author":"Hochhaus","year":"2019","journal-title":"Blood"},{"issue":"4760","key":"10.1016\/j.leukres.2020.106337_bib0435","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-speci\ufb01c P210 protein is the product of the BCR\/ABL hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0440","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.21915","article-title":"Characterization of chronic myeloid leukemia stem cells","volume":"86","author":"Gerber","year":"2011","journal-title":"Am. J. Hematol."},{"issue":"19","key":"10.1016\/j.leukres.2020.106337_bib0445","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1002\/cncr.31408","article-title":"The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia","volume":"124","author":"Ercaliskan","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2020.106337_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2867-12-52","article-title":"New insights into antigen specific immunotherapy for chronic myeloid leukemia","volume":"12","author":"Li","year":"2012","journal-title":"Cancer Cell Int."},{"issue":"11","key":"10.1016\/j.leukres.2020.106337_bib0455","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","article-title":"Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study","volume":"21","author":"Rojas","year":"2007","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.leukres.2020.106337_bib0460","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/cncr.24468","article-title":"Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial","volume":"115","author":"Jain","year":"2009","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2020.106337_bib0465","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/leu.2016.254","article-title":"PR1 peptide vaccine induces speci\ufb01c immunity with clinical responses in myeloid malignancies","volume":"31","author":"Qazilbash","year":"2017","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.leukres.2020.106337_bib0470","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/cgt.2016.80","article-title":"Therapeutic vaccination based on side population cells transduced by the granulocyte\u2013 macrophage colony-stimulating factor gene elicits potent antitumor immunity","volume":"24","author":"Sakamoto","year":"2017","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.leukres.2020.106337_bib0475","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-09-2046","article-title":"K562\/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate","volume":"16","author":"Smith","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"9","key":"10.1016\/j.leukres.2020.106337_bib0480","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1038\/bcj.2013.44","article-title":"Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562\/GVAX immunotherapy","volume":"3","author":"Qin","year":"2013","journal-title":"Blood Cancer J."},{"issue":"11","key":"10.1016\/j.leukres.2020.106337_bib0485","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrclinonc.2017.88","article-title":"Monitoring immune-checkpoint blockade: response evaluation and biomarker development","volume":"14","author":"Nishino","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2020.106337_bib0490","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","article-title":"Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression","volume":"114","author":"Mumprecht","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2020.106337_bib0495","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/leu.2015.26","article-title":"Blocking programmed cell death 1 in combination with adoptive cytotoxic T-cell transfer eradicates chronic myelogenous leukemia stem cells","volume":"29","author":"Riether","year":"2015","journal-title":"Leukemia"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212620300424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:29Z","timestamp":1758934829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212620300424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":99,"alternative-id":["S0145212620300424"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106337","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapeutic approaches in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2020.106337","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106337"}}